Results 191 to 200 of about 57,669 (284)
Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 4010-4018, May 2026.Abstract Aims To evaluate the steady‐state pharmacokinetics (PK) and glucodynamic effects of insulin efsitora alfa (efsitora) over a weekly interval in adults with type 2 diabetes (T2D). Materials and Methods This open‐label, multiple dose, euglycaemic clamp study was conducted in 56 insulin naïve adults with T2D (mean [±SD] age, 61.9 ± 5.98 years ...
Jennifer Leohr +11 more
wiley +1 more source
COVID-19 and diabetic ketoacidosis: National outcomes, predictors, and resource utilization in the United States. [PDF]
J Diabetes InvestigChia JE +4 more
europepmc +1 more source
Institutional factors in the management of adults with diabetic ketoacidosis in the UK: results of a national survey [PDF]
, 2015 Bull +5 more
core +1 more source
Economic burden of type 2 diabetes management in France according to clinical characteristics
Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 4019-4032, May 2026.Abstract Aim We sought to investigate the treatment, medication patterns, and economic burden of type 2 diabetes (T2D) in France. Materials and Methods This was a descriptive retrospective cross‐sectional study of a representative sample of adults in the national healthcare system claims database in 2022.
Bruno Guerci +9 more
wiley +1 more source
Cognitive Overload by Algorithm: Simulation Showed AI Is Not Ready to Lead Diabetic Ketoacidosis. [PDF]
Diabetes Metab Res RevMonzani A +3 more
europepmc +1 more source
The role of point-of-care 3-hydroxybutyrate testing in patients with type 2 diabetes undergoing coronary angiography [PDF]
, 2017 core +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 4055-4065, May 2026.Abstract Aims Real‐time continuous glucose monitors (rt‐CGM) have been found effective and economical for the treatment of diabetes in many countries. The objective of this study was to provide a cost‐effectiveness analysis of rt‐CGM versus self‐monitoring of blood glucose (SMBG) from the perspective of a healthcare payer in New Zealand.
Ryan G. Paul +4 more
wiley +1 more source
Construction and validation of a clinical prediction model for diabetic ketoacidosis. [PDF]
Front Med (Lausanne)Xu C, Jiang X, He Q, Xu P.
europepmc +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 4112-4120, May 2026.ABSTRACT Aims Evogliptin, a dipeptidyl peptidase‐4 inhibitor with a glucose‐dependent mechanism of action, is widely used as a monotherapy or in combination with other agents. However, observational studies in routine clinical settings remain limited.
Jun Hwa Hong +14 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 4205-4215, May 2026.ABSTRACT Aims Treatment options for post‐bariatric hypoglycaemia (PBH) are empirical. We aimed to investigate the efficacy and safety of acarbose and canagliflozin for the treatment of PBH. Materials and Methods We performed a randomised, double‐blinded, cross‐over, placebo‐controlled clinical trial where placebo, acarbose 50 mg thrice daily, and ...
Carolina B. Lobato +9 more
wiley +1 more source